These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2506054)

  • 1. Efficacy and pharmacokinetics of piretanide in patients with congestive heart failure.
    Marone C; Rivera B; Zwahlen H; Lahn W; Frey F
    Eur J Clin Invest; 1989 Aug; 19(4):378-83. PubMed ID: 2506054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure.
    Sherman LG; Liang CS; Baumgardner S; Charuzi Y; Chardo F; Kim CS
    Clin Pharmacol Ther; 1986 Nov; 40(5):587-94. PubMed ID: 3533372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute and long-term renal and metabolic effects of piretanide in congestive cardiac failure.
    McNabb WR; Noormohamed FH; Lant AF
    Br J Clin Pharmacol; 1988 Aug; 26(2):143-54. PubMed ID: 3207551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single dose comparison of piretanide and bumetanide in congestive cardiac failure.
    Homeida M; Roberts CJ; Dombey SL
    Br J Clin Pharmacol; 1979 Aug; 8(2):173-8. PubMed ID: 385025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of cardiac function on the diuretic and hemodynamic effects of the loop diuretic piretanide.
    Hasenfuss G; Holubarsch C; Herzog C; Knauf H; Spahn H; Mutschler E; Just H
    Clin Cardiol; 1987 Feb; 10(2):83-8. PubMed ID: 3815928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment.
    Noormohamed FH; McNabb WR; Dixey JJ; Lant AF
    J Pharmacol Exp Ther; 1990 Sep; 254(3):992-9. PubMed ID: 2395126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intravenous piretanide and furosemide in patients with congestive heart failure.
    Marsh JD; Nesto R; Glynn MA; Smith TW
    J Cardiovasc Pharmacol; 1982; 4(6):949-54. PubMed ID: 6185787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of piretanide, a potassium stable diuretic, on serum electrolytes in patients with congestive heart failure.
    Verho M; Bückert C; Freude J; Jaeger S; Pahnke K
    Pharmatherapeutica; 1985; 4(5):288-95. PubMed ID: 3906674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piretanide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Clissold SP; Brogden RN
    Drugs; 1985 Jun; 29(6):489-530. PubMed ID: 3891305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of piretanide and chlorothiazide in the treatment of cardiac failure.
    Gillies A; Morgan T; Myers J
    Med J Aust; 1980 Feb; 1(4):170-2. PubMed ID: 6990212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piretanide: a loop-active diuretic. Pharmacology, therapeutic efficacy and adverse effects.
    Marsh JD; Smith TW
    Pharmacotherapy; 1984; 4(4):170-80. PubMed ID: 6384944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of the loop diuretic piretanide in renal failure.
    Walter U; Röckel A; Lahn W; Heidland A; Heptner W
    Eur J Clin Pharmacol; 1985; 29(3):337-43. PubMed ID: 4076330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constant K+/Na+ excretion ratio during peak diuresis after piretanide but insignificant K+ loss during 24 hours.
    Knauf H; Mutschler E
    Eur J Clin Pharmacol; 1992; 43(1):23-7. PubMed ID: 1505604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral piretanide in chronic renal failure.
    Henderson IS; Beattie TJ; Kennedy AC; Dombey SL
    Br J Clin Pharmacol; 1982 Dec; 14(6):857-60. PubMed ID: 7150461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the short-term effects of the loop diuretic piretanide and furosemide in patients with renal insufficiency.
    Marone C; Reubi FC; Lahn W
    Eur J Clin Pharmacol; 1984; 26(4):413-8. PubMed ID: 6734705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.
    Arroyo V; Bosch J; Casamitjana R; Cabrera J; Rivera F; Rodés J
    Gut; 1980 Oct; 21(10):855-9. PubMed ID: 7439805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
    Sjöström P
    Scand J Urol Nephrol Suppl; 1988; 111():1-66. PubMed ID: 3201162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of a loop diuretic, piretanide, in severe cardiac insufficiency].
    Doglio GR; Pusajó JF; Bonfigli G; Hualde R; Lafourcade ES; Ortiz Maldonado HG
    Medicina (B Aires); 1984; 44(1):53-8. PubMed ID: 6535906
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical comparative trial of piretanide and furosemide in patients with advanced renal insufficiency. Drug levels and diuretic potency of single oral doses].
    Heuer LJ; Machnik H; Studt J; Fink R
    Arzneimittelforschung; 1983; 33(9):1318-21. PubMed ID: 6685516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a new diuretic (piretanide) compared with furosemide on renal diluting and concentrating mechanisms in patients with the nephrotic syndrome.
    Marone C; Reubi FC
    Eur J Clin Pharmacol; 1980; 17(3):165-71. PubMed ID: 7363930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.